Silence Therapeutics plc (SLNCF) Return on equity 2022–2025
Silence Therapeutics plc (SLNCF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-142.2%FY2025 · since FY2022: -184.9% → -142.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -142.2% | -108.4 pp |
| FY2024 | -33.8% | +212.8 pp |
| FY2023 | -246.6% | -61.7 pp |
| FY2022 | -184.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice